Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Revenue from awards and licenses $ 1,230,621 $ 2,589,783 $ 3,279,026 $ 33,570,048
Operating expenses:        
Research and development 27,522,989 22,152,001 82,156,926 66,117,114
General and administrative 7,681,573 5,534,493 23,120,020 17,367,202
Total operating expenses 35,204,562 27,686,494 105,276,946 83,484,316
Operating loss (33,973,941) (25,096,711) (101,997,920) (49,914,268)
Other income (expense), net:        
Other income (expense), net (4,972) 4,109,338 4,005 4,109,338
Interest income (expense), net (454,319) 292,854 (348,654) 1,076,166
Change in fair value of derivative liability (211,000) (211,000)
Foreign currency exchange loss, net (251,117) (96,282) (103,903) (144,193)
Other income (expense), net (921,408) 4,305,910 (659,552) 5,041,311
Net loss $ (34,895,349) $ (20,790,801) $ (102,657,472) $ (44,872,957)
Net loss per share, basic and diluted [1] $ (0.43) $ (0.32) $ (1.37) $ (0.71)
Weighted average number of common shares outstanding, basic and diluted [1] 81,879,119 64,660,017 75,037,418 63,638,447
[1] Warrants and options that have not been exercised have been excluded from the diluted calculation as all periods presented have a net loss and the impact of these securities would be anti-dilutive